Takeda Laboratory, manufacturer of the Qdenga vaccine, will expand the production of doses against dengue fever through a partnership signed with the Indian laboratory Biological E.
In a statement, Takeda informed that Biological E will begin producing 50 million doses of Qdinga annually, allowing it to reach the goal of delivering 100 million doses by 2030.
According to the statement, the partnership addresses the specific need to provide doses for national vaccination programs in order to help protect the most vulnerable populations.
The Takeda laboratory confirmed that “these doses will eventually be available for acquisition by the governments of affected countries by 2030, at the latest, to support national immunization programs.”
Brazil
Qdenga was integrated into the Unified Health System (SUS) in December last year and began its distribution this month to 521 municipalities selected by the Ministry of Health to immunize children and adolescents.
The selection of municipalities, according to the volume, was necessary due to the limited amount of doses provided by the manufacturer. With Takeda's announcement, it is expected that more Brazilian cities will be covered and other groups immunized against dengue.
Emily Brontë is a journalist and feature writer specialising in culture, entertainment, literature, and current affairs. She is dedicated to producing clear, accurate reporting that helps readers stay informed about developments in the UK and around the world.
